CagriSema
Also known as: Semaglutide + Cagrilintide
Key Facts: CagriSema
- Category
- Weight Loss
- FDA Status
- Not FDA Approved
- Clinical Status
- Phase 3 Clinical Trials
- Administration
- Subcutaneous injection weekly
- Typical Dose
- Limited community data available
- Frequency
- See research protocols
- Evidence Level
- Human Trials
- Duration
- Long-term use expected
What to Expect
A combination of semaglutide and cagrilintide (amylin analog) in development. Aims to provide superior weight loss through dual mechanisms.
Mechanism of Action
Combines GLP-1 receptor agonism (semaglutide) with amylin receptor agonism (cagrilintide). Amylin adds satiety signaling and slows gastric emptying through different pathways than GLP-1.
Research Summary
Phase 2 trials showed up to 17.1% weight loss at 32 weeks, potentially superior to semaglutide alone. Phase 3 trials (REDEFINE program) ongoing for obesity and diabetes.
Dosing Information
Typical Dosingⓘ
Community experience
Limited community data available
See research dosing
See research protocols
Research Dosingⓘ
Scientific studies
Doses from clinical trials
Doses from Studies
Semaglutide 2.4mg + Cagrilintide 2.4mg weekly
Duration
Long-term use expected
Administration
Subcutaneous injection weekly
Timing & Administration
Best Time to Take
Before bed or morning (fasted)
Follow specific peptide protocol
Food Recommendation
Take on empty stomach
Why This Timing?
GH-related peptides work best on an empty stomach to maximize growth hormone release.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Nausea
- ●Vomiting
- ●Diarrhea
- ●Constipation
- ●GI events (72-80% vs 34-40% placebo)
- ●Higher GI effects than semaglutide alone
- ●Investigational - not yet approved
References
Related Peptides
Peptides commonly compared with CagriSema or used in similar applications.
Retatrutide
Clinical TrialsA triple agonist targeting GLP-1, GIP, and glucagon receptors. Represents the next evolution beyond dual agonists like tirzepatide, showing unprecedented weight loss in trials.
Weight LossOrforglipron
Clinical TrialsAn oral non-peptide GLP-1 receptor agonist. Could provide injection-free alternative to semaglutide and tirzepatide.
Weight LossSurvodutide
Clinical TrialsA dual GLP-1/glucagon receptor agonist in development for obesity and NASH. Combines appetite suppression with increased energy expenditure.
Weight LossCagrilintide
Clinical TrialsA long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).
Weight LossSemaglutide
FDAA GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. One of the most effective pharmaceutical weight loss interventions available.
Weight LossTirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials.
Weight LossWant updates on CagriSema research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.